Published November 9, 2023 | Version v1
Journal article Open

Granulation fluid and Pore former on morphology, Mechanical test and Dissolution Rate of microcrystalline cellulose base Alpha-lipoic acid pellet formulation on improving cardiovascular performance

Authors/Creators

  • 1. Department of pharmaceutical Faculty of pharmacy Bagiyatallah University of Medical Sciencies Teheran Iran

Description

Background:Slow conversion and dissolution of microcrystalline cellulose (MCC) extrudates is a weakness for water-insoluble drugs. This study aim was to determine the growing holes of the granulation liquid affect the physical and chemical properties of alpha-lipoic acid (a lipophilic substance) and its effect on improving cardiovascular performance.

Methods: Pellets containing alpha-lipoic acid, MCC and forming pores were prepared using a non-aqueous granulation liquid by extrusion-spheroidization method, and the micrometric and mechanical properties and drug release of alpha-lipoic acid with effects on cardiovascular function were investigated. The entire formulation of the produced medicinal compounds had pellets of appropriate spherical shape and size.

Results: The dissolution power and elastic modulus of the pellets change with the addition of cavitation agent and granulating liquid, and the dissolution rate of alpha lipoic acid. When the pore agent and the new granulation liquid are used together, the creation of a more porous matrix, faster dissolution, and a significant increase in the solubility of the drug, all lead to an increase in the dissolution rate of the drug and a better effect of the drug on the function of the target organ and improve the function of an organ such as cardiovascular. Combined modification of these factors increased the disintegration of hydrophobic drugs.

Conclusion: new extrusion-spheronization technique can be used to enhance the solubility of alpha-lipoic acid in the form of multi-particle dosage in improving drugs effect on cardiovascular performance and this technique can also be used with other medications that are not very water-soluble.

Keywords: Alpha-lipoic acid pellets, Dissolution rate, Pore former, drug solubility, granulation fluid, cardiovascular performance.

Files

5 Granulation fluid and Pore former on morphology,.pdf

Files (642.2 kB)

Additional details

References

  • Pandey V, Gilhotra RM, Kohli S. Granulated colloidal silicon dioxide-based self-microemulsifying tablets, as a versatile approach in enhancement of solubility and therapeutic potential of anti-diabetic agent: formulation design and in vitro/in vivo evaluation. Drug Development and Industrial Pharmacy. 2017;43(6):1023-32.
  • 2. Celebioglu A, Uyar T. Encapsulation and stabilization of α-lipoic acid in cyclodextrin inclusion complex electrospun nanofibers: Antioxidant and fast-dissolving α-lipoic acid/cyclodextrin nanofibrous webs. Journal of agricultural and food chemistry. 2019;67(47):13093-107.
  • 3. Zawar LR, Bari SB. Preparation, characterization and in vivo assessment of repaglinide nanosuspension for oral bioavailability improvement. Recent Patents on Drug Delivery & Formulation. 2018;12(3):162-9.
  • 4. Association AAP. National center for biotechnology information. pubchem compound summary for CID 12699, N-Nitroso-N-methylurea. retrieved 24. 2020.
  • 5. Bernkop‐Schnürch A, Reich‐Rohrwig E, Marschütz M, Schuhbauer H, Kratzel M. Development of a sustained release dosage form for α‐lipoic acid. II. Evaluation in human volunteers. Drug development and industrial pharmacy. 2004;30(1):35-42.
  • 6. Ikuta N, Tanaka A, Otsubo A, Ogawa N, Yamamoto H, Mizukami T, et al. Spectroscopic studies of R (+)-α-lipoic acid—cyclodextrin complexes. International Journal of Molecular Sciences. 2014;15(11):20469-85.
  • 7. Carbone C, Arena E, Pepe V, Prezzavento O, Cacciatore I, Turkez H, et al. Nanoencapsulation strategies for the delivery of novel bifunctional antioxidant/σ1 selective ligands. Colloids and Surfaces B: Biointerfaces. 2017;155:238-47.
  • 8. Brufani M, Figliola R. (R)-α-lipoic acid oral liquid formulation: pharmacokinetic parameters and therapeutic efficacy. Acta Bio-Medica: Atenei Parmensis. 2014;85(2):108-15.
  • 9. Mahboob A, Farhat SM, Iqbal G, Babar MM, Nabavi SM, Ahmed T. Alpha-lipoic acid-mediated activation of muscarinic receptors improves hippocampus-and amygdala-dependent memory. Brain research bulletin. 2016;122:19-28.
  • 10. Hermann R, Mungo J, Cnota PJ, Ziegler D. Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms. Clinical pharmacology: advances and applications. 2014:195-204.
  • 11. Canosa S, Paschero C, Carosso A, Leoncini S, Mercaldo N, Gennarelli G, et al. Effect of a combination of myo-inositol, alpha-lipoic acid, and folic acid on oocyte morphology and embryo morphokinetics in non-PCOS overweight/obese patients undergoing IVF: a pilot, prospective, randomized study. Journal of Clinical Medicine. 2020;9(9):2949.
  • 12. Çoban Ö, Yıldırım S, Bakır T. Alpha-lipoic acid and cyanocobalamin co-loaded nanoemulsions: Development, characterization, and evaluation of stability. Journal of Pharmaceutical Innovation. 2021:1-11.
  • 13. Bechgaard H, Nielsen GH. Controlled-release multiple-units and single-unit doses a literature review. Drug Development and Industrial Pharmacy. 1978;4(1):53-67.
  • 14. Lam M, Ghafourian T, Nokhodchi A. Optimising the release rate of naproxen liqui-pellet: a new technology for emerging novel oral dosage form. Drug Delivery and Translational Research. 2020;10:43-58.
  • 15. Muley S, Nandgude T, Poddar S. Extrusion–spheronization a promising pelletization technique: In-depth review. Asian journal of pharmaceutical sciences. 2016;11(6):684-99.
  • 16. Goyanes A, Souto C, Martínez-Pacheco R. Co-processed MCC-Eudragit® E excipients for extrusion–spheronization. European Journal of Pharmaceutics and Biopharmaceutics. 2011;79(3):658-63.
  • 17. Dukić-Ott A, Thommes M, Remon JP, Kleinebudde P, Vervaet C. Production of pellets via extrusion–spheronisation without the incorporation of microcrystalline cellulose: a critical review. European journal of pharmaceutics and biopharmaceutics. 2009;71(1):38-46.
  • 18. Ibrahim MA, Al-Anazi FK. Enhancement of the dissolution of albendazole from pellets using MTR technique. Saudi Pharmaceutical Journal. 2013;21(2):215-23.
  • 19. Tho I, Sande SA, Kleinebudde P. Pectinic acid, a novel excipient for production of pellets by extrusion/spheronisation: preliminary studies. European journal of pharmaceutics and biopharmaceutics. 2002;54(1):95-9.
  • 20. Goyanes A, Martínez-Pacheco R. New co-processed MCC-based excipient for fast release of low solubility drugs from pellets prepared by extrusion-spheronization. Drug development and industrial pharmacy. 2015;41(3):362-8.
  • 21. Wlosnewski JC, Kumpugdee-Vollrath M, Sriamornsak P. Effect of drying technique and disintegrant on physical properties and drug release behavior of microcrystalline cellulose-based pellets prepared by extrusion/spheronization. Chemical Engineering Research and Design. 2010;88(1):100-8.
  • 22. Chatlapalli R, Rohera BD. Physical characterization of HPMC and HEC and investigation of their use as pelletization aids. International journal of pharmaceutics. 1998;161(2):179-93.
  • 23. Lustig-Gustafsson C, Johal HK, Podczeck F, Newton J. The influence of water content and drug solubility on the formulation of pellets by extrusion and spheronisation. European journal of pharmaceutical sciences. 1999;8(2):147-52.
  • 24. Mallipeddi R, Saripella KK, Neau SH. Use of coarse ethylcellulose and PEO in beads produced by extrusion–spheronization. International journal of pharmaceutics. 2010;385(1-2):53-65.
  • 25. Millili G, Schwartz J. The strength of microcrystalline cellulose pellets: the effect of granulating with water/ethanol mixtures. Drug Development and Industrial Pharmacy. 1990;16(8):1411-26.
  • 26. Bouwman A, Henstra M, Westerman D, Chung J, Zhang Z, Ingram A, et al. The effect of the amount of binder liquid on the granulation mechanisms and structure of microcrystalline cellulose granules prepared by high shear granulation. International journal of pharmaceutics. 2005;290(1-2):129-36.
  • 27. Širca J, Pintye-Hodi K, Burjan T, Planinšek O, Srčič S. Physicochemical properties of granulating liquids and their influence on microcrystalline cellulose pellets obtained by extrusion-spheronisation technology. International journal of pharmaceutics. 2005;291(1-2):99-111.
  • 28. Sriamornsak P, Nunthanid J, Luangtana-anan M, Puttipipatkhachorn S. Alginate-based pellets prepared by extrusion/spheronization: A preliminary study on the effect of additive in granulating liquid. European Journal of pharmaceutics and biopharmaceutics. 2007;67(1):227-35.
  • 29. Chamsai B, Sriamornsak P. Novel disintegrating microcrystalline cellulose pellets with improved drug dissolution performance. Powder technology. 2013;233:278-85.
  • 30. Sun CC. Critical roles of porosity in tableting properties characterization and solids formulation development. American Pharmaceutical Review. 2005;8(6):102-7.
  • 31. Schröder M, Kleinebudde P. Structure of disintegrating pellets with regard to fractal geometry. Pharmaceutical research. 1995;12:1694-700.
  • 32. Nicklasson F, Alderborn G. Modulation of the tabletting behaviour of microcrystalline cellulose pellets by the incorporation of polyethylene glycol. European journal of pharmaceutical sciences. 1999;9(1):57-65.
  • 33. Costa F, Pais A, Sousa J. Analysis of formulation effects in the dissolution of ibuprofen pellets. International journal of pharmaceutics. 2004;270(1-2):9-19.
  • 34. Kleinebudde P. Shrinking and swelling properties of pellets containing microcrystalline cellulose and low substituted hydroxypropylcellulose: I. Shrinking properties. International journal of pharmaceutics. 1994;109(3):209-19.
  • 35. Jachowicz R, Nürnberg E, Pieszczek B, Kluczykowska B, Maciejewska A. Solid dispersion of ketoprofen in pellets. International journal of pharmaceutics. 2000;206(1-2):13-21.